Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Jori B, et al. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Current Oncol 2022 Sep 16;29(9):6628-6634. doi:10.3390/curroncol29090520

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Roeper J, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 2022 Jan;11(1):4-13. doi:10.21037/tlcr-21-754

TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib

Roeper J, et al. TP53 mutations as AN independent prognostic factor in 2nd AND FURTHER line THERAPY – EGFR mutated Non-Small Cell Lung Cancer IV PATIENTS treated with Osimertinib. Transl Lung Cancer Res 2021 Jan;11(1):4-13. doi: 10.21037/tlcr-21-754

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

Berger LA, et al. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. J Thorac Oncol 2018 Dec;13(12):e243-e246. doi:10.1016/j.jtho.2018.08.2025 I2

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

Keppens C, et al. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn 2018 Jul;20(4):483-494. doi:10.1016/j.jmoldx.2018.03.006

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Scheel AH, et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018 Feb;72(3):449-459. doi: 10.1111/his.13375

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

Michels S, et al. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. J Thorac Oncol 2016 Jan;11(1):122-7. doi:10.1016/j.jtho.2015.09.016

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

Scheel AH, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016 Oct;29(10):1165-72. doi:10.1038/modpathol.2016.117

Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing

Christopoulos P, et al. Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer

Schatz S, et al. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. Cancers 2020 Jun 24;12(6):1685. doi: 10.3390/cancers12061685

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC

Roeper J, et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget 2020 Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Michels S, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020.

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)

Frank R, et al. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Canc Res 2018 Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416